Scorpius Holdings, Inc.

Equities

HTBX

US42237K4094

Pharmaceuticals

Delayed OTC Markets 17:52:01 02/07/2024 BST 5-day change 1st Jan Change
0.0255 USD -15.56% Intraday chart for Scorpius Holdings, Inc. -10.84% -94.21%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Scorpius Holdings, Inc.(OTCPK:SCPX) dropped from S&P TMI Index CI
Scorpius Holdings Faces Delisting by NYSE American; Trading Suspended MT
Certain Convertible Notes of Scorpius Holdings, Inc. are subject to a Lock-Up Agreement Ending on 7-JUN-2024. CI
Certain Stock Options of Scorpius Holdings, Inc. are subject to a Lock-Up Agreement Ending on 7-JUN-2024. CI
Certain Common Stock of Scorpius Holdings, Inc. are subject to a Lock-Up Agreement Ending on 7-JUN-2024. CI
Scorpius Holdings, Inc. and Beyond Imagination Announce Trailblazing Partnership to Utilize Autonomous AI-Powered Humanoid Robots for American Biomanufacturing CI
Scorpius Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Scorpius Holdings, Inc. Announces Major Expansion in San Antonio with New Storage and Testing Facility CI
Top Midday Decliners MT
Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding CI
Scorpius Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Scorpius Holdings Gets Non-Compliance Notice From NYSE American MT
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Focus Turns to -2- DJ
US Stock Futures Flat Ahead of Powell Speech After Reaching Record Highs on Thursday MT
Scorpius Holdings, Inc. Wins Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University CI
Scorpius Closes $1.5 Million Public Offering MT
Scorpius Holdings Prices Stock Offering at $0.15 a Share MT
Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023 CI
NightHawk Biosciences, Inc. will Change its Name to Scorpius Holdings, Inc CI
Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary CI
Scorpius Holdings, Inc. announced that it has received $2.25 million in funding from Elusys Holdings Inc. CI
NightHawk?s Scorpius BioManufacturing Subsidiary Receives Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program CI
NightHawk Biosciences Postpones Planned Name Change MT
Nighthawk?S Scorpius Biomanufacturing Subsidiary Commences Work on Preclinical Program for New Client CI
Chart Scorpius Holdings, Inc.
More charts
Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0302
Average target price
-
Consensus
  1. Stock Market
  2. Equities
  3. HTBX Stock
  4. News Scorpius Holdings, Inc.
  5. Scorpius Holdings Prices Stock Offering at $0.15 a Share